Cite
MLA Citation
IB McInnes et al.. “OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2.” Annals of the rheumatic diseases, vol. 76, n.d., p. 145. http://access.bl.uk/ark:/81055/vdc_100135162013.0x000061